Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples

American Journal of Clinical Pathology

Volumn 129, Issue 6, 2008, Pages 899-906

  Baumhoer, Daniel ^a   Tornillo, Luigi ^a   Stadlmann, Sylvia ^a   Roncalli, Massimo ^b   Diamantis, Eva Karamitopoulou ^c   Terracciano, Luigi M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Glypican 3; GPC3; Hepatocellular carcinoma; Tissue microarray

Indexed keywords

GLYPICAN 3; GLYPICAN; GPC3 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LUNG SQUAMOUS CELL CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TISSUE MICROARRAY; EMBRYONAL CARCINOMA; FEMALE; LIVER TUMOR; LUNG TUMOR; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PREDICTION AND FORECASTING; SQUAMOUS CELL CARCINOMA; TESTIS TUMOR;

CARCINOMA, EMBRYONAL; CARCINOMA, HEPATOCELLULAR; CARCINOMA, SQUAMOUS CELL; FEMALE; GLYPICANS; HUMANS; LIPOSARCOMA; LIVER; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASMS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; TESTICULAR NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 45949107581     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/HCQWPWD50XHD2DW6     Document Type: Article

References (37)

1. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108:497-501.
2. Lander AD, Stipp CS, Ivins JK. The glypican family of heparan sulfate proteoglycans: major cell-surface proteoglycans of the developing nervous system. Perspect Dev Neurobiol. 1996;3:347-358.
3. Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245-6254.
4. Veugelers M, De Cat B, Ceulemans H, et al. Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans. J Biol Chem. 1999;274:26968-26977.
5. DeBaun MR, Ess J, Saunders S. Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. Mol Genet Metab. 2001;72:279-286.
6. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12:241-247.
7. Gonzalez AD, Kaya M, Shi W, et al. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol. 1998;141:1407-1414.
8. Man XB, Tang L, Zhang BH, et al. Upregulation of glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver Int. 2005;25:962-966.
9. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene. 2001;20:7408-7412.
10. Lin H, Huber R, Schlessinger D, et al. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res. 1999;59:807-810.
11. Murthy SS, Shen T, De Rienzo A, et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 2000;19:410-416.
12. Peters MG, Farias E, Colombo L, et al. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat. 2003;80:221-232.
13. Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 2000;89:418-422.
14. Lage H, Dietel M, Froschle G, et al. Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies. Int J Clin Pharmacol Ther. 1998;36:58-60.
15. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997;57:5179-5184.
16. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001;48:558-564.
17. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89-97.
18. Sung YK, Hwang SY, Park MK, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003;94:259-262.
19. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591-1598.
20. Lugli A, Tornillo L, Mirlacher M, et al. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples. Am J Clin Pathol. 2004;122:721-727.
21. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999;5:1966-1975.
22. Hirohashi S, Ishak KG, Kojiro M, et al. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, ed. Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000:159-172. World Health Organization Classification of Tumours.
23. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
24. Zlobec I, Minoo P, Baker K, et al. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer. 2007;43:1101-1107.
25. Zlobec I, Vuong T, Hayashi S, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer. 2007;96:793-800.
26. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249-2256.
27. Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 2001;194:349-357.
28. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst. 1999;91:1758-1764.
29. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154:981-986.
30. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111:316-322.
31. Lu ZL, Luo DZ, Wen JM. Expression and significance of tumor-related genes in HCC. World J Gastroenterol. 2005;11:3850-3854.
32. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725-734.
33. Abdul-Al HM, Makhlouf HR, Wang G, et al. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008;39:209-212.
34. Zynger DL, Dimov ND, Luan C, et al. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575.
35. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs. 2005;19:71-77.
36. Ikuta Y, Nakatsura T, Kageshita T, et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res. 2005;11:8079-8088.
37. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004;10:6612-6621.